Date: 2017-05-16
Type of information: Construction of new premises
Compound:
Company: Cambrex (USA - NJ)
Therapeutic area: Technology - Services
Type agreement: construction of new premises
Action mechanism:
Disease:
Details:
- • On May 16, 2017, Cambrex announced that it is to expand pilot plant capabilities at its High Point, NC facility with the installation of a fourth reactor suite. The $2.4M investment will increase the site’s reactor capacity by around 30%.
- The new 400 sq. ft. suite, which is being constructed to meet growing business demand, will feature two 2000 liter reactors and a 0.6 sq. m. Hastelloy filter dryer, and is expected to be fully operational by early 2018.
- In a second investment at the High Point site, Cambrex is to upgrade its analytical chromatography data systems for QC and analytical R & D to new, Empower 3 software. Empower will be introduced in Q3 and Q4 of 2017 and will bring enhanced capability, integrity and compliance to the site’s analytical systems, in line with the increasingly stringent demands of the FDA and EMA among other agencies.
- Cambrex acquired the 35,000sq. ft. High Point site, formerly PharmaCore, in October 2016.
Financial terms:
Latest news:
Is general: Yes
